Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical Advances in Hematology & OncologySystemic Management of Brain Metastases in HER2+ Breast Cancer in 2022

Up to half of all patients with metastatic HER2+ breast cancer will eventually acquire brain metastases, which are associated with reduced overall survival and decreased quality of life. This comprehensive review examines current recommendations in 1st, 2nd, and later line therapies, discusses the status of novel agents, and provides recommendations to standardize care.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form